Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

41. An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence

An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence Das Gupta R, Caiado M, Bamber L Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared five different options for the treatment of moderate-to-severe stress urinary incontinence (SUI). The options compared were: current standard treatment in the authors' setting; duloxetine alone as first-line treatment; duloxetine

NHS Economic Evaluation Database.2006

42. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training

Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor (...) incontinence (SUI). The strategies compared were: pelvic floor muscle training (PFMT); duloxetine alone; the use of duloxetine after an inadequate response to PFMT; and no treatment. Duloxetine is a serotonin and norepinephrine re-uptake inhibitor that acts on the sacral spinal cord. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population As this was a modelling study, the target population comprised a cohort of 1,000 women aged 50 years and older who suffered from

NHS Economic Evaluation Database.2006

44. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Vis P M, Van Baardewijk M, Einarson T R CRD summary This generally well-conducted review concluded that duloxetine and venlafaxine (...) -XR are effective, compared with placebo, for the treatment of major depressive disorder. Venlafaxine tends to have a favourable trend in remission and response rates compared with duloxetine. Conclusions relating to comparisons with placebo seem reliable, but the conclusion regarding the superiority of venlafaxine over duloxetine is not fully supported by the results. Authors' objectives To compare indirectly the efficacy and safety of extended-release (XR) venlafaxine and duloxetine

DARE.2005

45. Duloxetine for fibromyalgia - horizon scanning review

Duloxetine for fibromyalgia - horizon scanning review Duloxetine for fibromyalgia - horizon scanning review Duloxetine for fibromyalgia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Duloxetine for fibromyalgia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 (...) Authors' objectives This study aims to summarise the currently available evidence on Duloxetine for fibromyalgia Authors' conclusions Duloxetine (Yentreve, Cymbalta, LY 248686) is a dual serotonin and noradrenaline re-uptake inhibitor (SNRI) in phase III trials for the management of the symptoms of fibromyalgia. If successful in licensing it will be the first pharmaceutical licensed for fibromyalgia. Two 12 week randomised, placebo controlled trials in 207 patients and 354 women, found that duloxetine

Health Technology Assessment (HTA) Database.2005

46. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder van Baardewijk M, Vis P M, Einarson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), in the treatment of moderate to severe major depressive disorder (MDD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The hypothetical study population comprised patients

NHS Economic Evaluation Database.2005

48. Duloxetine for major depressive disorder and stress urinary incontinence

Duloxetine for major depressive disorder and stress urinary incontinence Duloxetine for major depressive disorder and stress urinary incontinence Duloxetine for major depressive disorder and stress urinary incontinence Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian (...) Coordinating Office for Health Technology Assessment. Duloxetine for major depressive disorder and stress urinary incontinence. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of duloxetine hydrochloride (Trade Mark: Cymbalta) for the treatment of major depressive disorder and stress urinary incontinence in women. Authors' conclusions Duloxetine is another choice in the growing list of marketed

Health Technology Assessment (HTA) Database.2004

50. Cymbalta (Duloxetine Hydrochloride)

Cymbalta (Duloxetine Hydrochloride) Drug Approval Package: Cymbalta (Duloxetine Hydrochloride) NDA #021427 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Cymbalta (Duloxetine Hydrochloride) Capsules Company: Eli Lilly & Co., Inc. Application No.: 021427 Approval Date: 8/03/2004 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) Chemistry Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) Clinical Pharmacology

FDA - Drug Approval Package2004